Royal Philips and the Singapore Institute of Advanced Medicine Holdings (SAM) announced a collaboration with Varian Medical Systems and IBA Worldwide to build the new Advanced Medicine Oncology Centre based at Biopolis, the international biomedical research hub in Singapore.
The oncology center will provide world-class imaging, treatment delivery and clinical informatics technologies with the intent to comprehensively address the region’s fast-growing number of people confronted with cancer.
SAM is driving the collaboration by investing up to SGD 100 million (approximately USD 72 million) towards the development of a center of excellence for oncology in the Southeast Asia region.
The new research, training and treatment center will provide cutting-edge oncology solutions for use by healthcare professionals and researchers. Projected to open in stages from 2018 onwards, the center will also aim to provide a platform for professional training to meet the evolving needs of the healthcare industry.
Through research, clinical trials and development of leading cancer treatment therapies, the Advanced Medicine Oncology Centre will house new innovations and treatment protocols developed via a multi-disciplinary approach for better and more personalized patient care, potentially improved outcomes and a better on-going quality of life for patients.
“The new Advanced Medicine Oncology Centre aligns with the founding goal of the Singapore Institute of Advanced Medicine Holdings to provide earlier detection and first-time-right diagnosis of cancer as well as safer, more cost effective treatment by advancing care enabled through research, technology and education,” said Dr. Djeng Shih Kien, Founder and Chairman, Singapore Institute of Advanced Medicine Holdings.
“I am proud to be leading this milestone with our partners, marking a step forward in the treatment of cancer, which affects much of humanity.”
The Advanced Medicine Oncology Centre will house a range of Philips’ advanced diagnostic imaging systems and clinical informatics. In addition to Philips’ Ingenia MR and IQon spectral CT systems, the center will have two of Philips’ Vereos PET/CT scanners , the world’s first and only fully digital PET/CT systems.
Vereos uses Philips’ proprietary Digital Photon Counting (DPC) technology resulting in improved detectability and characterization of small lesions . It offers uncompromised lesion detectability and quantification at half the PET dose  together with overall sensitivity gains compared to analog  systems.
Varian’s ProBeam® Compact system will provide high-quality proton therapy. The ProBeam® is the only single room system capable of fully rotational intensity modulated proton therapy (IMPT). IBA’s Cyclone Kiube technology will enable complete on-site production and utilization of PET radiopharmaceuticals and tracers for lesion visualization using Philips digital PET/CT. This will help the oncology center to deliver new treatments with a unique combination of speed, flexibility and cost efficiency.
The center will use Philips IntelliSpace Portal 9.0 for advanced visual analysis and quantification of medical images helping clinicians to assess and quickly diagnose conditions using clinical applications that are optimized for patient evaluation throughout the treatment process.
“Cancer affects people from all walks of life and is among the leading causes of death worldwide, accounting for more than 4 million deaths in Asia in 2016 ,” said Diederik Zeven, General Manager, Health Systems, Philips ASEAN Pacific.
“Philips is enabling the advancement of medical research through our deep heritage in healthcare innovation and collaboration with medical partners. The new Advanced Medicine Oncology Centre is well-positioned to spearhead cancer research and treatment in Singapore and the region and we are very proud to be a strategic partner.”
“This center will be the first installation of Varian’s ProBeam Compact proton therapy system, which is designed to enable space-constrained sites such as this to offer state-of-the-art technology for cancer patients,” said Dr. Moataz Karmalawy, General Manager of Varian’s Particle Therapy division.
“This center will open up additional opportunities for both education and research. Singapore is joining an exclusive group of countries that have facilities like these to advance our understanding of not only proton therapy, but also immunotherapy and other cell-based treatments.”